Literature DB >> 32147907

An update on the implications of cyclin D1 in melanomas.

Lucia González-Ruiz1, Miguel Ángel González-Moles2,3, Isabel González-Ruiz2, Isabel Ruiz-Ávila3,4, Ángela Ayén5, Pablo Ramos-García2.   

Abstract

Cyclin D1 is a protein encoded by the CCND1 gene, located on 11q13 chromosome, which is a key component of the physiological regulation of the cell cycle. CCND1/cyclin D1 is upregulated in several types of human tumors including melanoma and is currently classified as an oncogene that promotes uncontrolled cell proliferation. Despite the demonstrated importance of CCND1/cyclin D1 as a central oncogene in several types of human tumors, its knowledge in melanoma is still limited. This review examines data published on upregulation of the CCND1 gene and cyclin D1 protein in the melanoma setting, focusing on the pathways and molecular mechanisms involved in the activation of the gene and on the clinical and therapeutic implications.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CCND1; cyclin D1; melanoma; skin carcinogenesis

Year:  2020        PMID: 32147907     DOI: 10.1111/pcmr.12874

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  10 in total

1.  Single Time Frame Overview of the Genetic Changes in Conjunctival Melanoma from Intraepithelial Disease to Invasive Melanoma: A Study of 4 Exenteration Specimens Illustrating the Potential Role of Cyclin D1.

Authors:  Hardeep Singh Mudhar; Sachin S Salvi; Daniel Pissaloux; Arnaud de La Fouchardiere
Journal:  Ocul Oncol Pathol       Date:  2021-11-17

Review 2.  Hallmarks of Cancer Applied to Oral and Oropharyngeal Carcinogenesis: A Scoping Review of the Evidence Gaps Found in Published Systematic Reviews.

Authors:  Miguel Ángel González-Moles; Saman Warnakulasuriya; María López-Ansio; Pablo Ramos-García
Journal:  Cancers (Basel)       Date:  2022-08-08       Impact factor: 6.575

3.  [MiR-744-5p inhibits the proliferation, invasion, and migration of clear-cell renal cell carcinoma cells by targeting CCND1].

Authors:  K Lei; W Xie; T Sun; Y Liu; X Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-05-20

Review 4.  Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity.

Authors:  Nischal Koirala; Nandini Dey; Jennifer Aske; Pradip De
Journal:  Int J Mol Sci       Date:  2022-06-11       Impact factor: 6.208

5.  Cyclin F Downregulation Affects Epithelial-Mesenchymal Transition Increasing Proliferation and Migration of the A-375 Melanoma Cell Line.

Authors:  Adrian Krajewski; Maciej Gagat; Klaudia Mikołajczyk; Magdalena Izdebska; Agnieszka Żuryń; Alina Grzanka
Journal:  Cancer Manag Res       Date:  2020-12-22       Impact factor: 3.989

6.  Association of Melanoma-Risk Variants with Primary Melanoma Tumor Prognostic Characteristics and Melanoma-Specific Survival in the GEM Study.

Authors:  Danielle R Davari; Irene Orlow; Peter A Kanetsky; Li Luo; Klaus J Busam; Ajay Sharma; Anne Kricker; Anne E Cust; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Lidia Sacchetto; Terence Dwyer; David C Gibbs; David W Ollila; Colin B Begg; Marianne Berwick; Nancy E Thomas
Journal:  Curr Oncol       Date:  2021-11-16       Impact factor: 3.677

7.  Cyclin D1 and PRAME expression in distinguishing melanoma in situ from benign melanocytic proliferation of the nail unit.

Authors:  Young Jae Kim; Chang Jin Jung; Youngkyoung Lim; Chong Hyun Won; Hyoungmin Na; Woo Jin Lee; Sung Eun Chang; Mi Woo Lee; Chan-Sik Park
Journal:  Diagn Pathol       Date:  2022-04-28       Impact factor: 2.644

8.  RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1.

Authors:  Hai-Zhou Wu; Lan-Ya Li; Shi-Long Jiang; Yi-Zhi Li; Xiao-Mei Shi; Xin-Yuan Sun; Zhuo Li; Yan Cheng
Journal:  Front Pharmacol       Date:  2022-09-20       Impact factor: 5.988

Review 9.  Current understanding of epigenetics role in melanoma treatment and resistance.

Authors:  Mohsen Karami Fath; Ali Azargoonjahromi; Asma Soofi; Faezeh Almasi; Shahnaz Hosseinzadeh; Saeed Khalili; Kamran Sheikhi; Saeid Ferdousmakan; Soroor Owrangi; Minoovash Fahimi; Hamidreza Zalpoor; Mohsen Nabi Afjadi; Zahra Payandeh; Navid Pourzardosht
Journal:  Cancer Cell Int       Date:  2022-10-12       Impact factor: 6.429

Review 10.  CDK4/6 Inhibitors in Melanoma: A Comprehensive Review.

Authors:  Mattia Garutti; Giada Targato; Silvia Buriolla; Lorenza Palmero; Alessandro Marco Minisini; Fabio Puglisi
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.